Catalyst Calendar

Wed, May 27, 2026

1 updates

7:00 AM

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m.

Enrollment • Phase 3Enrollment completion Wed, Mar 31, 2027, 8:30 AM ETmediwound.com

Thu, May 7, 2026

1 updates

MDWD

8:00 AM

MediWound to Report First Quarter 2026 Financial Results

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced

mediwound.com